Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.

Kim S, Han J, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ, Lee JE.

Anticancer Res. 2011 Nov;31(11):3767-73.

PMID:
22110198
3.

[An updated review at molecular pharmacological level for the mechanism of anti-tumor, antioxidant and immunoregulatory action of silibinin].

Wang HJ, Jiang YY, Lu P, Wang Q, Ikejima T.

Yao Xue Xue Bao. 2010 Apr;45(4):413-21. Review. Chinese.

PMID:
21355204
4.

Understanding the dual nature of CD44 in breast cancer progression.

Louderbough JM, Schroeder JA.

Mol Cancer Res. 2011 Dec;9(12):1573-86. doi: 10.1158/1541-7786.MCR-11-0156. Epub 2011 Oct 4. Review.

5.

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.

Bosch-Barrera J, Menendez JA.

Cancer Treat Rev. 2015 Jun;41(6):540-6. doi: 10.1016/j.ctrv.2015.04.008. Epub 2015 Apr 27. Review.

PMID:
25944486

Supplemental Content

Support Center